SCHEMBL259362

SCHEMBL259362

CNc1ccc(C(=O)Nc2cccc(C)c2)cn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.73
KMT2A Q03164 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
ALDH1A1 P00352 2/20 0.73
LMNA P02545 1/20 0.73
RXFP1 Q9HBX9 1/20 0.60
GAA P10253 1/20 0.58
KCNK3 O14649 4/20 0.56
KCNK9 Q9NPC2 3/20 0.56
KCNH2 Q12809 1/20 0.56
NPC1 O15118 2/20 0.56
TP53 P04637 2/20 0.56
RAB9A P51151 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
POLB P06746 2/20 0.54
HCAR3 P49019 1/20 0.51
TSHR P16473 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4253868 0.85 P4HTM (0.67) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259470 0.83 MEN1 (0.64) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259364 0.82 MEN1 (0.75) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259296 0.82 KMT2A (0.80) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259474 0.82 ALDH1A1 (0.62) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259419 0.80 MEN1 (0.71) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL16495590 0.79 MEN1 (0.70) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL9845394 0.79 HCAR3 (0.55) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6935345 0.79 MEN1 (0.70) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL259706 0.78 MEN1 (0.77) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.